ReviewCurrent urology reports2016
Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health.
Review in Current urology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Metformin reverses oxandrolone-induced anxiety-like behavior and amygdalar neurochemical dysregulation in male rats.Psychopharmacology · 2026Article
- The Uses of Anabolic Androgenic Steroids Among Athletes; Its Positive and Negative Aspects- A Literature Review.Journal of multidisciplinary healthcare · 2023Review
- Recent advancement in the treatment of boys and adolescents with hypogonadism.Therapeutic advances in endocrinology and metabolism · 2022Review
- Anabolic-Androgenic Steroid Misuse: Mechanisms, Patterns of Misuse, User Typology, and Adverse Effects.Journal of sports medicine (Hindawi Publishing Corporation) · 2021Review
- Sudden Cardiac Death in Anabolic-Androgenic Steroid Users: A Literature Review.Medicina (Kaunas, Lithuania) · 2020Review
- Management of Anabolic Steroid-Induced Infertility: Novel Strategies for Fertility Maintenance and Recovery.The world journal of men's health · 2020Review
- Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.Sexual medicine reviews · 2019Review
- Novel Therapy for Male Hypogonadism.Current urology reports · 2018Review
- Androgen Treatment in Adolescent Males With Hypogonadism.American journal of men's healthReview
- Knowledge of and Attitudes Toward the Use of Anabolic-Androgenic Steroids among the Population of Jeddah, Saudi Arabia.Journal of microscopy and ultrastructureArticle
- Use of Anabolic-Androgenic Steroids and Male Fertility: A Systematic Review and Meta-analysis.Journal of human reproductive sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has recently been renewed interest in novel clinical applications of the anabolic-androgenic steroid (AAS) testosterone and its synthetic derivatives, particularly given with the rising popularity of testosterone supplementation therapy (TST) for the treatment of male hypogonadism. In this manuscript, we provide a brief review of the history of AAS and discuss clinical applications of two of the more well-known AAS: nandrolone and oxandrolone. Both agents exhibit favorable myotrophic/androgenic ratios and have been investigated for effectiveness in numerous disease states. We also provide a brief synopsis of selective androgen receptor modulators (SARMs) and postulate how these orally active, non-aromatizing, tissue-selective agents might be used in contemporary andrology. Currently, the applications of testosterone alternatives in hypogonadism are limited. However, it is tempting to speculate that these agents may one day become accepted as alternatives, or adjuncts, to the treatment of male hypogonadism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.